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Abstract
Introduction: The degree of association and type of causal
versus non-causal relationship between pneumonia and lung
cancer (LC) are evolving discussions. We reviewed Englishlanguage publications on the degree of association between
pneumonia and subsequent LC.
Methods: We searched the PubMed database using keywords for pneumonia, LC, and Chlamydia infection. We selected peer-reviewed studies of patients with pneumonia and
LC. Case reports and other literature reviews were excluded
from this review.
Results: Five studies examined the incidence and/or risk of
LC for a total of 415,750 patients, and four studies examined cases with Chlamydia pneumoniae chronic infection at
the time of diagnosis of LC for a total of 1,467 patients. The
overall risk and/or incidence of LC after pneumonia was from
2.3% to 10% for a median follow-up ranging from 109 days

Introduction
According to the World Health Organization, lung cancer is the second most common cancer worldwide, with
approximately 2.2 million new cases diagnosed in 2020,
accounting for almost 25% of all cancers and 36% of
all cancer deaths.[1, 2] In the US, there were 218,893
new cases of lung cancer and about 142,080 deaths from
lung cancer.[3] Each year, more people die of lung cancer than colon, breast, and prostate cancers combined.
Lung cancer mainly occurs in people older than 45 with
an average age of 70 years.[4] Regardless of tobacco
smoking status, the overall chance that a man will develop lung cancer in his lifetime is about 1 in 15 (and
for a woman is 1 in 17), and for those who do smoke,
the risk is much higher.[4]
The degree of association and type of causal versus non-
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to 4.2 years. Three studies reported current tobacco smoking status, which ranged from 27.7% to 45% among those
with LC. A history of prior malignancy was reported in 22.5%
of patients with LC. Chlamydia immunoglobulin (Ig) A and
LC were statistically non-significantly associated regardless
of the age of the patients. In one study, Chlamydia heat shock
protein (HSP)-60 IgG ≥1:50 was associated with significantly
increased odds of LC in two respective models (odds ratios of
1.34 [95% confidence interval (CI) 1.06–1.69] and 1.30 [95%
CI 1.02–1.67]). A fourth study reported C. pneumoniae IgA ≥
64 titers to be 58%, 29%, and 5.5% among patients with LC,
those without LC, and healthy blood donors, respectively.
Conclusions: The incidence of LC was reported to range
from 2.3% to 10.3% following an episode of pneumonia.
There is limited evidence of the association of chronic
Chlamydia infection with LC, and Chlamydia could be a
causal cofactor of LC.

causal relationship between pneumonia and lung cancer are evolving discussions. Pneumonia has been characterized as a surrogate of underlying lung cancers,
while other reports have indicated some type of bidirectional causal relationship. According to the 2019
Infectious Diseases Society of America and American
Thoracic Society guidelines for community-acquired
pneumonia (CAP), the frequency of lung cancer in patients recovering from CAP ranges between 1.3% and
4%.[5] On the other hand, it was reported that abnormal chest images are found in up to 5% of cases of
the unsuspected non-malignant condition. A chest Xray after pneumonia has traditionally been performed
to search for underlying lung cancer. Still, current recommendations advise against follow-up chest imaging
in adult patients whose symptoms resolve within 5–7
days.[5]
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Brenner et al. reviewed the association between lung
diseases and the risk of lung cancer.[6] This review
included 22 studies, but many were not about pneumonia or were concerned with self-reported pneumonia.[6] Ang et al. found a significant positive association between history of pneumonia and lung cancer
risk with a pooled summary estimate of 1.49 (95% [CI]
1.23–1.66).[7] We reviewed current literature in the English language to examine the degree of association between pneumonia and subsequent lung cancer, focusing on the incidence and risk of lung cancer after a diagnosis of pneumonia.

Methods
Database search strategy
We conducted a search of the PubMed database using terms such as “pneumonia AND lung cancer,”
“community-acquired pneumonia AND lung cancer,”
and “Chlamydia AND lung cancer.” Due to the unique
relationship between Chlamydia infection and cancer,
it was analyzed separately from overall pneumonia.
Inclusion criteria
Peer-reviewed prospective or retrospective studies of
patients with pneumonia and lung cancer were included.
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cancer. In addition, a history of prior malignancy was
reported in 23% of patients with lung cancer compared
to 15% of those without lung cancer. Similarly, a history of tuberculosis was present in 12% of those with
lung cancer and 9% of those without.
Chlamydia pneumoniae chronic infection and lung cancer
Among four studies of C. pneumoniae, three examined
Chlamydia immunoglobulin (Ig) G and A titers, and one
of these studies also examined Chlamydia heat shock
protein-60 (CHSP-60) (Figures 1 and 2a–b). Laurila et
al. and Chaturvedi et al. reported statistically insignificant associations of Chlamydia IgA with lung cancer for
patients younger than 60 years, older than 70 years, and
regardless of age (Figures 1 and 2a).[14, 15] Chaturvedi
et al. reported that CHSP-60 IgG titers ≥1:50 were associated with significantly increased odds of lung cancer
diagnosis in two respective models (odds ratios [OR]
of 1.34 [95% CI 1.06–1.69] and 1.30 [95% CI 1.02–1.67]).
The fourth study of Chlamydia examined a prospective cohort of patients with and without lung cancer
compared with healthy blood donors.[16] All study
participants were tobacco smokers or former smokers.
The frequency of C. pneumoniae IgA ≥64 titers was
58%, 29%, and 5.5% among patients with lung cancer,
those without lung cancer, and healthy blood donors.
Among healthy blood donors, 20% of males and 9% of
females had C. pneumoniae IgA titers ≥64.

Exclusion criteria

Discussion

Case reports and other literature reviews were excluded from this review.

This review includes eight retrospective studies and
one prospective study from Scandinavia, Canada, and
the US. These studies examined (i) the incidence
and/or risk of lung cancer in adults after pneumonia
and (ii) cases with positive tests for C. pneumoniae, including totals of 415,750 and 1,467 participants, respectively.

Results
A total of 13 studies were selected for this review. Four
studies were excluded due to patients’ self-reported
respiratory infection, antibiotic treatment as a predictor of lung cancer, or pneumonia in childhood. Finally, we selected (i) five studies that examined the incidence and/or risk of lung cancer (Table 1) for a total
of 415,750 patients [8-12] and (ii) four studies of cases
with and without Chlamydia pneumoniae chronic infection at the time of the diagnosis of lung cancer, with a
total of 1,467 patients (Figures 1 and 2).[8, 10-17]
Incidence and risk for lung cancer
The overall risk or incidence of lung cancer after pneumonia ranged from 2.3% to 10% for a median followup ranging from 109 days to 4.2 years. Except for the
study of Mortensen et al., which included 98% males,
males accounted for 53% to 77% of study participants.
Three studies reported current tobacco smoking status,
ranging from 28% to 45% among those with lung cancer, 10% to 23% greater frequency than those without
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There are many potential confounders to take into consideration regarding the association between lung cancer and pneumonia. Male sex, aging, tobacco smoking,
previous cancer, and history of tuberculosis are significantly more common among those with lung cancer
after a diagnosis of pneumonia (Table 1). However,
odds ratios remain statistically significant after adjustment for these confounders, indicating an independent
association of pneumonia and lung cancer (Figures 1
and 2).
From a causality perspective, pneumonia could result
from post-obstructive lung cancer or anatomic mucosal
barrier compromises. Secondly, microbiome changes
due to pneumonia could result in lung cancer or vice
versa. Concerning the first possibility, a traditionally
recommended practice was to repeat a chest X-ray
(CXR) several weeks after the episode of pneumonia.
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1,103 (2.7)
7,572 (18.6)

Rheumatologic disease

Stroke

All studies were retrospective in design. Abbreviations: COPD, chronic obstructive pulmonary disease; SD, standard deviation.
a
Standardized cancer incidence ratio for lung cancer. Other values in the column reflect any cancer;
b
Median except where otherwise specified;
c
Non-pulmonary.

Tuberculosis

5,148 (12.6)

Renal disease

133 (0.3)

Prior metastatic solid tumor

6,116 (15.0)

Peripheral vascular disease

Prior malignancyc

1,362 (3.3)
6,079 (14.9)

Peptic ulcer disease

2,891 (7.1)

Myocardial infarction

17,535 (43.0)

20,814 (51.1)

352 (10.6)

14 (17.7)

607 (18.3)

14,370 (35.3)

77.1±6.8

Diabetes mellitus

5,812 (20.4)

10,641 (37.3)

15,754 (55.3)

39,983 (98.1)

40,744

5,887 (2.52a )
4.2 years

Pneumonia

Cancer

COPD

49,622 (14.5)

104,146
(30.4)

177,918
(51.9)

342,609

Pneumonia

561 (14.9)

124 (3.3)

382 (10.2)

846 (22.5)

33 (0.9)

527 (14.0)

135 (3.6)

244 (6.5)

1,430 (38.0)

2,129 (56.6)

842 (22.4)

1,700 (45.2)

76.5±6.3

3,711 (98.7)

297 days

3,760 (9.2)

Cancer

Mortensen 2010, n (%)

10,620 (26.1)

22 (12.4)

26 (14.7)

105 (59.3)

49 (27.7)

122 (68.9)

177 (2.5)

Cancer

Søgaard 2015, n (%)

Heart failure
24 (30.4)

932 (13.2)

Non-smoker

Comorbidities

896 (12.7)

2,324 (33.0)

22 (27.8)

Former smoker

575 (17.3)

3,905 (55.4)

7,044

Current smoker

76 (96.2)

52 (65.8)

109 days

79 (2.3)

Pneumonia

2,678 (38.0)

2,010 (60.6)

1,762 (53.1)

3,319

Cancer

Søyseth 2007, n (%)

Age ≥75

Age ≥50

Age, mean±SD

Male

Baseline characteristics

Time to diagnosisb

n

Pneumonia

Tang 2011, n (%)

Table 1. Incidence of subsequent lung cancer in cohorts of patients with pneumonia.

1,899 (8.6)

5,606 (25.4)

4,251 (19.3)

8,367 (38.0)

14,623 (66.4)

22,034

Pneumonia

274 (12.0)

463 (20.4)

445 (19.6)

822 (36.1)

1,757 (77.3)

≤1y: 67.7%
>1y: 32.3%

2,274 (10.3)

Cancer

Lin 2013, n (%)

ULJRI
Lung Cancer, Pneumonia, and C. pneumoniae infection

3

ULJRI

Lung Cancer, Pneumonia, and C. pneumoniae infection

Figure 1. Association between serological evidence of C. pneumoniae and risk of lung cancer in three studies. Odds ratios and 95% confidence
intervals displayed on a logarithmic scale.
Chaturvedi*: Case-control pairs matched by age, sex, year of randomization, follow-up time in study, smoking status, pack-years of smoking,
and time since quitting smoking; adjusted for matching variables.
Chaturvedi†: Case-control pairs matched by age, sex, year of randomization, follow-up time in study, smoking status, pack-years of smoking,
time since quitting smoking; adjusted for matching factors and for race, level of education, BMI at enrolment, regular use of aspirin/ibuprofen,
family history of lung cancer, history of heart disease, and history of emphysema/bronchitis.
Laurila: Case control pairs matched by age, supplementation group, study center, and timing of serum sampling; adjusted for self-reported years
of smoking and daily cigarette consumption.
Littman: Case-control pairs matched on year of randomization, age at randomization, sex, exposure cohort (sex, smoking, exposure to asbestos), pilot or efficacy study, smoking status at baseline; adjusted for years smoked, cigarettes smoked per day, education, and BMI.
Abbreviations: OR, odds ratio; CI, confidence interval; MIF, micro-immunofluorescence; Ig, immunoglobulin; HSP-60, heat shock protein 60.
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a) Stratified by age.

b) Stratified by histological type.

Figure 2. Association between serological evidence of C. pneumoniae and risk of lung cancer in two studies, stratified by (a) age and (b)
histological type. Odds ratios and 95% confidence intervals displayed on a logarithmic scale.
Laurila: Case control pairs matched by age, supplementation group, study center, and timing of serum sampling; adjusted for self-reported years
of smoking and daily cigarette consumption.
Littman: Case-control pairs matched on year of randomization, age at randomization, sex, exposure cohort (sex, smoking, exposure to asbestos), pilot or efficacy study, smoking status at baseline; adjusted for years smoked, cigarettes smoked per day, education, and BMI.
Abbreviations: OR, odds ratio; CI, confidence interval; Ig, immunoglobulin.
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Current guidelines do not support this practice.[5] Tang
et al. reported that the incidence of lung cancer after
pneumonia is about 1% within 90 days and 2% over
five years, suggesting that a CXR is not warranted after pneumonia.[8] The second possibility is that the
interaction of the microbiome with lung cancer is bidirectional. Changes in the lung microbiome could
lead to local lung changes, generating carcinogenic factors contributing to cancer development and vice versa.
Granulicatella is one of the predominant bacteria in the
sputum and bronchoalveolar lavage of patients with
lung cancer.[18, 19] It has been proposed that the anaerobic environment secondary to lung cancer and the
increasing volume of pyridoxal and polyamin compounds contribute to the selective growth of Granulicatella.[20] Furthermore, changes in airway microbiota
have been associated with upregulation of the P13K
pathway in patients with lung cancer.[21, 22] Similarly,
chronic exposure to cytolethal distending toxins (CDT)
produced by many bacteria, including Salmonella typhi
[23], has been linked to impairment of the DNA damage response pathway and upregulation of mitogenactivated protein kinase pathway, favoring tumor survival and growth.[24] CDT-producing bacteria were
more likely to be found near tumors rather than healthy
colonic cells in human colorectal cancer patients.[25]
C. pneumoniae IgA ≥ 1:16 and lung cancer
There was a lack of association between C. pneumoniae IgA titers ≥1:16 and lung cancer for persons aged
<60, >70, and regardless of age.[13] When stratified
by type of lung cancer, C. pneumoniae IgA titers ≥ 1:16
were significantly associated with squamous lung cancer only.[13] This particular association of C. pneumoniae to squamous lung cancer could be because it was
the most common type of cancer in this study.
CHSP-60 IgG and lung cancer
CHSP-60 is expressed by C. pneumoniae during its
life cycle, including the chronic infection, triggering
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chronic inflammation.[26] Antibodies to CHSP-60 reflecting chronic infection and inflammation have been
reported to be associated with tissue damage [26],
and they could be a reliable marker of the mechanism of Chlamydia in the development of lung cancer.
Chaturvedi et al. reported a statistically significant association between CHSP-60 IgG titers ≥1:50 and lung
cancer.[14] Interestingly, this association was present
from 2 to 5 years before lung cancer diagnosis, suggesting the potential causality of chronic Chlamydia infection. Helicobacter pylori, human papillomavirus, and
Epstein–Barr virus, among other pathogens, are recognized etiologies of cancers in the setting of chronic infection. Although we observed some degree of association between chronic Chlamydia infection and lung
cancer, current findings are not clear enough to draw
strong conclusions, and likely, Chlamydia is merely a
causal cofactor of lung cancer. This interpretation is
bolstered by the fact that not all lung cancers are associated with Chlamydia infection, and not all Chlamydia
infections result in cancer.
Our review has strengths and weaknesses. To our
knowledge, our review is the first to evaluate studies in
the English-language literature on the relation of pneumonia, chronic Chlamydia infection, and lung cancer.
Furthermore, this review involved a critical analysis of
the role of the microbiome in lung carcinogenesis. Concerning weaknesses, our review included a small number of studies, most of which were retrospective in design, in large part due to the limited number of studies
in the field.
In conclusion, the incidence of lung cancer was reported to range from 2.3% to 10.3% following an
episode of pneumonia. There is limited evidence of the
association of chronic Chlamydia infection with lung
cancer, and Chlamydia could be a causal cofactor of
lung cancer. Metagenomic studies are needed to examine the changes in the lung microbiome triggering
upregulation of the P13K signaling pathway.
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15. Laurila AL, Anttila T, Läärä E, et al. Serological evidence of an association between Chlamydia pneumoniae
infection and lung cancer. Int J Cancer 1997; 74(1):314. doi: 10.1002/(sici)1097-0215(19970220)74:1<31::aidijc6>3.0.co;2-1. PMID: 9036866.
16. Koyi H, Brandén E, Gnarpe J, Gnarpe H, Steen B. An
association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study. Apmis
2001; 109(9):572-80. doi: 10.1034/j.1600-0463.2001.d01177.x. PMID: 11878709.
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